L-dopa
Levodopa is the standard therapy in PD.
Loading study record…
Loading study record…
Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2026-04-08
What this record can show
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Linked local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Interventions
Levodopa is the standard therapy in PD.
Etoricoxib, is a selective cyclooxygenase-2 inhibitor. Prostaglandins (PG) are produced from arachidonic acid by the constitutively expressed cyclooxygenase-1(COX-1) and by the inducible COX-2 enzymes and are secreted mainly by astrocytes and microglia.
Eligibility
primary outcomes
Time frame: 6 months
\- Change in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score
Publications
No exact PMID-linked public article is currently readable locally.